| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Regulation FD Disclosure
In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics (the “Company”) reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consis... |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
SAN FRANCISCO, November 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements 2 Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not ... |
| 25 Sep 2026 |
8-K: Other Events
In August 2023, Nektar Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach ... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Nektar Therapeutics (the “Company”) is entering a quiet period beginning September 8, 2026 and continuing until the public announcement of data from the 24-week off treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegald... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
SAN FRANCISCO, Aug 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended Ju... |
| 05 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the Annual Meeting of the Stockholders of Nektar Therapeutics, a Delaware corporation (the “Company”), held on June 4, 2026 (the “Annual Meeting”), the following actions were taken. The proposals below are described in detail in the C... |
| 08 May 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
As further set forth in this agreement (this “Agreement”), Nektar Therapeutics, a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Guggenheim Securities, LLC and H.C. Wain... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. |
| 23 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. Nektar Therapeutics, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 3,532,609 shares (the “Firm Shares”) of its common... |
| 20 Apr 2026 |
8-K: Regulation FD Disclosure
On April 20, 2026, Nektar Therapeutics (the “Company”) announced it had approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This announcement reflects the Company’s estimates based solely up... |
| 20 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Phase 2b REZOLVE-AA 52-Week Topline Results: 16-Week Extension Treatment Period Rezpegaldesleukin in Patients with Severe-to-Very-Severe Alopecia Areata April 20, 2026 |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
SAN FRANCISCO, Mar 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025. |
| 13 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. Nektar Therapeutics, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 6,603,449 shares (the “Firm Shares”) of its co... |
| 10 Feb 2026 |
8-K: Regulation FD Disclosure
On February 10, 2026, Nektar Therapeutics (the “Company”) announced it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This announcement reflects the Company’s estimates based sol... |
| 10 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Phase 2b REZOLVE-AD: Topline Results from 36-Week Maintenance Period Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis February 10, 2026 Exhibit 99.2 |
| 27 Jan 2026 |
8-K: Regulation FD Disclosure
As Nektar Therapeutics (the “Company”) prepares for analyses of data (the “Maintenance Data”) from the 36-week maintenance period of its Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis... |
| 16 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Phase 2b REZOLVE-AA Topline Results from 36-Week Induction Treatment Period Rezpegaldesleukin in Patients with Severe-to-Very-Severe Alopecia Areata December 16, 2025 |
| 21 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
(b) On November 21, 2025, Nektar Therapeutics (“Nektar”) announced that Mark A. Wilson will step down as Chief Legal Officer of Nektar, effective as of December 31, 2025. Mr. Wilson’s departure is not the result of any disagreement with ... |
| 10 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting |
Loading...